Delving into the Latest Updates on Recombinant human interferon α2b(Lee's Pharmaceutical Holdings Ltd.) with Synapse

to assess the efficacy and safety of recombinant human interferon α-2b gel (Yallaferon®) for the treatment of patients with cervical high-risk HPV infections; to analyze the HPV type infections and clinical negative conversion.
285 patients with positive high risk HPV infection were randomized into interferon gel group and control group at ratio of 2:1 (203 patients in treatment group and 82 patients in control group). The patients in treatment group received 1g recombinant human α-2b interferon gel every other day for consecutive 3 courses of treatment, whereas no treatment was conducted in control group.

Start Date01 Mar 2011

Sponsor / Collaborator

Lee's Pharmaceutical Holdings Ltd.

100 Clinical Results associated with Recombinant human interferon α2b(Lee's Pharmaceutical Holdings Ltd.)

Login to view more data

100 Translational Medicine associated with Recombinant human interferon α2b(Lee's Pharmaceutical Holdings Ltd.)

Login to view more data

100 Patents (Medical) associated with Recombinant human interferon α2b(Lee's Pharmaceutical Holdings Ltd.)

Login to view more data

3

Literatures (Medical) associated with Recombinant human interferon α2b(Lee's Pharmaceutical Holdings Ltd.)

01 Dec 2020·BMC BiotechnologyQ4 · ENGINEERING & TECHNOLOGY

Development and biological activity of long-acting recombinant human interferon-α2b

Q4 · ENGINEERING & TECHNOLOGY

ArticleOA

Author: Yao, Lihong ; Zheng, Lishu ; Ma, Fenlian ; Zhang, Qian ; Zhu, Luyan ; Wang, Chao ; Gao, Hanchun

AbstractBackgroundThe type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects. However, because the half-life of IFN is short, its clinical application is limited. Increasing the yield and biological activity of IFN while extending its half-life is currently the focus of IFN research.ResultsTwo novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b. They were designated IFN-1CTPON (fused at the C-terminus of rhIFN-α2b) and IFN-2CTPON (fused at both the C-terminus and N-terminus of rhIFN-α2b). Monoclonal CHO cell strains stably and efficiently expressing the IFNs were successfully selected with methotrexate (MTX), and the highest expression levels were 1468 mg/l and 1196 mg/l for IFN-1CTPON and IFN-2CTPON, respectively. The proteins were purified with affinity chromatography and molecular sieve chromatography. IFN-1CTPON and IFN-2CTPON showed antiviral and antiproliferative activities in vitro. Notably, the half-life of IFN-1CTPON and IFN-2CTPON in vivo were three-fold and two-fold longer than that of commercially available rhIFN-α2b.ConclusionsCHO cell strains stably expressing long-acting rhIFN-α2b were screened. The purified IFN-CTPON protein has biological activity and an extended half-life, and therefore potential applications.

01 Jan 2014·Oncology LettersQ4 · MEDICINE

Multiple microvenular hemangioma: A case report

Q4 · MEDICINE

Article

Author: Li, Yan ; Ai, Dong Fang ; Li, Ping ; Jindal, Aikaj

The current study reports a case of multiple microvenular hemangioma (MH). A 35-year-old male presented with dark red maculopapules on the trunk and limbs that had been apparent for 5 years. The number of lesions exceeded 100 in total. A histological examination demonstrated multiple, irregular, branching venules in the dermis, without any endothelial atypia. On immunohistochemical analysis of the vascular structures, the endothelial cells stained positive for CD31, CD34 and factor VIII, and the perivascular cells stained positive for SMA and HHF-35. These observations were consistent with a diagnosis of MH, and should be differentiated from the most common differential diagnosis of patch-stage Kaposi's sarcoma. There was no clear effect following topical application of recombinant human interferon α-2b gel.

American Journal of Translational Research

Clinical efficacy of recombinant human interferon α-2b gel combined with LEEP conization in treating cervical intraepithelial neoplasia with comorbid high-risk HPV infection

Article

Author: Huang, Xialing ; Liu, Xiaoxia ; Zhang, Shaohua

OBJECTIVETo evaluate the clinical efficacy of recombinant human interferon α-2b (rHuINF α-2b) gel combined with loop electrosurgical excision procedure (LEEP) conization in treating cervical intraepithelial neoplasia (CIN) with comorbid high-risk human papillomavirus (HR-HPV) infection.METHODSA retrospective analysis was conducted on the clinical data of 202 CIN patients with HR-HPV infection who were treated at Wuhan Yaxin General Hospital between July 2021 and February 2024. Among these patients, 106 received treatment with rHuINF α-2b gel combined with LEEP conization (study group), and the other 96 were treated with LEEP conization alone (control group). The two groups were compared in terms of efficacy on CIN, HPV clearance, vaginal bleeding duration, hospital stay and occurrence of adverse reactions. Patient prognosis within six months post-treatment was analyzed, and the risk factors affecting prognosis were analyzed through logistic regression.RESULTSThe control group experienced notably longer vaginal bleeding duration and hospital stay than the study group (all P<0.0001). The study group showed a notably higher cure rate of CIN than the control group and presented a notably lower rate of persistent or residual CIN than the control group (P=0.0026). Six months after treatment, the total effective HPV clearance rate in the study group was greatly higher than that in the control group (P=0.0010). However, there was no insignificant difference between the two groups in the incidence of adverse reactions (P=0.4807). According to logistic regression analysis, age, grade of CIN, course of disease and treatment regimen were independent risk factors for patient prognosis.CONCLUSIONFor CIN patients with comorbid high HPV risk infection, rHuINF α-2b gel combined with LEEP conization can effectively treat CIN, clear HPV, and shorten the duration of vaginal bleeding and hospitalization, without increasing adverse reactions. In addition, age, grade of CIN, course of disease and treatment regimen were independent risk factors for the prognosis of patients.

100 Deals associated with Recombinant human interferon α2b(Lee's Pharmaceutical Holdings Ltd.)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB05	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Uterine Cervicitis	CN	Lee's Pharmaceutical Holdings Ltd.	07 Sep 2005
Condylomata Acuminata	CN	Zhaoke Pharmaceutical (Hefei) Co., Ltd.	01 Jan 2001
Herpes Genitalis	CN	Zhaoke Pharmaceutical (Hefei) Co., Ltd.	01 Jan 2001
Herpes Labialis	CN	Zhaoke Pharmaceutical (Hefei) Co., Ltd.	01 Jan 2001
Herpes Zoster	CN	Zhaoke Pharmaceutical (Hefei) Co., Ltd.	01 Jan 2001
Uterine Diseases	CN	Zhaoke Pharmaceutical (Hefei) Co., Ltd.	01 Jan 2001

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Herpes Zoster	Phase 3	-	Lee's Pharmaceutical Holdings Ltd.	01 Apr 2023
HPV16 Infection	Preclinical	CN	Lee's Pharmaceutical Holdings Ltd.	01 Sep 2015
Gynecological infection	Preclinical	-	Lee's Pharmaceutical Holdings Ltd.	01 Mar 2011
Human Papillomavirus Infection	Preclinical	-	Lee's Pharmaceutical Holdings Ltd.	01 Mar 2011